Trial reportCells2019
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Trial report in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01442935 (Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.Cells · 2023Pooled it
- Pooled it
- Impact of methodological variability on the prognostic performance of circulating tumor DNA in colorectal cancer: A systematic review and meta-analysis.The journal of liquid biopsy · 2026Review
- Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.The British journal of surgery · 2026Article
- New prognostic and predictive scoring systems for colorectal cancer liver metastases.ESMO open · 2026Review
- Multistep ctDNA Monitoring of Minimal Residual Disease in Colorectal Cancer Liver Metastases: From Tissue NGS to Highly Sensitive Digital PCR Platforms.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic Value of Circulating Tumor DNA for Recurrence and Survival in Patients Undergoing Local Treatment for Initially Unresectable RAS/RAF Mutated Colorectal Cancer Liver Metastases.Annals of surgical oncology · 2026Article
- MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.BMC cancer · 2025Article
- Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma.BMC cancer · 2025Article
- Review
- Precision Oncology Framework Using Circulating Tumor Cells.International journal of molecular sciences · 2025Review
- New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical Issues.International journal of molecular sciences · 2025Review
- Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis.Journal of the National Cancer Center · 2025Article
- Gravity-based microfiltration reveals unexpected prevalence of circulating tumor cell clusters in ovarian and colorectal cancer.Communications medicine · 2025Article
- Circulating tumor cell markers for early detection and drug resistance assessment through liquid biopsy.Frontiers in oncology · 2025Review
- Unveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk.Frontiers in immunology · 2025Review
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment of mutational status and of response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) detection. CRC patients with potentially resectable LM were treated with first-line triplet or doublet chemotherapy combined with targeted therapy. CTC (Cellsearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.